These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

413 related items for PubMed ID: 23804425

  • 1.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 2. A HGF/cMET autocrine loop is operative in multiple myeloma bone marrow endothelial cells and may represent a novel therapeutic target.
    Ferrucci A, Moschetta M, Frassanito MA, Berardi S, Catacchio I, Ria R, Racanelli V, Caivano A, Solimando AG, Vergara D, Maffia M, Latorre D, Rizzello A, Zito A, Ditonno P, Maiorano E, Ribatti D, Vacca A.
    Clin Cancer Res; 2014 Nov 15; 20(22):5796-807. PubMed ID: 25212607
    [Abstract] [Full Text] [Related]

  • 3. Targeting the pro-survival protein MET with tivantinib (ARQ 197) inhibits growth of multiple myeloma cells.
    Zaman S, Shentu S, Yang J, He J, Orlowski RZ, Stellrecht CM, Gandhi V.
    Neoplasia; 2015 Mar 15; 17(3):289-300. PubMed ID: 25810013
    [Abstract] [Full Text] [Related]

  • 4. Targeting phospho-MARCKS overcomes drug-resistance and induces antitumor activity in preclinical models of multiple myeloma.
    Yang Y, Chen Y, Saha MN, Chen J, Evans K, Qiu L, Reece D, Chen GA, Chang H.
    Leukemia; 2015 Mar 15; 29(3):715-26. PubMed ID: 25179733
    [Abstract] [Full Text] [Related]

  • 5. Antimyeloma activity of the orally bioavailable dual phosphatidylinositol 3-kinase/mammalian target of rapamycin inhibitor NVP-BEZ235.
    McMillin DW, Ooi M, Delmore J, Negri J, Hayden P, Mitsiades N, Jakubikova J, Maira SM, Garcia-Echeverria C, Schlossman R, Munshi NC, Richardson PG, Anderson KC, Mitsiades CS.
    Cancer Res; 2009 Jul 15; 69(14):5835-42. PubMed ID: 19584292
    [Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8. FTY720 induces apoptosis in multiple myeloma cells and overcomes drug resistance.
    Yasui H, Hideshima T, Raje N, Roccaro AM, Shiraishi N, Kumar S, Hamasaki M, Ishitsuka K, Tai YT, Podar K, Catley L, Mitsiades CS, Richardson PG, Albert R, Brinkmann V, Chauhan D, Anderson KC.
    Cancer Res; 2005 Aug 15; 65(16):7478-84. PubMed ID: 16103102
    [Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10. Molecular target characterization and antimyeloma activity of the novel, insulin-like growth factor 1 receptor inhibitor, GTx-134.
    Liang SB, Yang XZ, Trieu Y, Li Z, Zive J, Leung-Hagesteijn C, Wei E, Zozulya S, Coss CC, Dalton JT, Fantus IG, Trudel S.
    Clin Cancer Res; 2011 Jul 15; 17(14):4693-704. PubMed ID: 21632854
    [Abstract] [Full Text] [Related]

  • 11. NEDD8 Inhibition Overcomes CKS1B-Induced Drug Resistance by Upregulation of p21 in Multiple Myeloma.
    Huang J, Zhou Y, Thomas GS, Gu Z, Yang Y, Xu H, Tricot G, Zhan F.
    Clin Cancer Res; 2015 Dec 15; 21(24):5532-42. PubMed ID: 26156395
    [Abstract] [Full Text] [Related]

  • 12. c-Met is a potentially new therapeutic target for treatment of human melanoma.
    Puri N, Ahmed S, Janamanchi V, Tretiakova M, Zumba O, Krausz T, Jagadeeswaran R, Salgia R.
    Clin Cancer Res; 2007 Apr 01; 13(7):2246-53. PubMed ID: 17404109
    [Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 18. OSU-03012, a novel celecoxib derivative, is cytotoxic to myeloma cells and acts through multiple mechanisms.
    Zhang S, Suvannasankha A, Crean CD, White VL, Johnson A, Chen CS, Farag SS.
    Clin Cancer Res; 2007 Aug 15; 13(16):4750-8. PubMed ID: 17699852
    [Abstract] [Full Text] [Related]

  • 19. Galectin-9 exhibits anti-myeloma activity through JNK and p38 MAP kinase pathways.
    Kobayashi T, Kuroda J, Ashihara E, Oomizu S, Terui Y, Taniyama A, Adachi S, Takagi T, Yamamoto M, Sasaki N, Horiike S, Hatake K, Yamauchi A, Hirashima M, Taniwaki M.
    Leukemia; 2010 Apr 15; 24(4):843-50. PubMed ID: 20200560
    [Abstract] [Full Text] [Related]

  • 20. Inhibition of c-Met with the specific small molecule tyrosine kinase inhibitor SU11274 decreases growth and metastasis formation of experimental human melanoma.
    Kenessey I, Keszthelyi M, Krámer Z, Berta J, Adám A, Dobos J, Mildner M, Flachner B, Cseh S, Barna G, Szokol B, Orfi L, Kéri G, Döme B, Klepetko W, Tímár J, Tóvári J.
    Curr Cancer Drug Targets; 2010 May 15; 10(3):332-42. PubMed ID: 20370683
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 21.